Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Phillips Wealth Planners LLC

Phillips Wealth Planners LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,372 shares of the biopharmaceutical company’s stock after selling 799 shares during the period. Phillips Wealth Planners LLC’s holdings in Gilead Sciences were worth $349,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in GILD. Norges Bank acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $1,789,254,000. FMR LLC lifted its position in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares during the period. GAMMA Investing LLC lifted its position in Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock valued at $285,761,000 after purchasing an additional 2,532,070 shares during the period. Northern Trust Corp lifted its position in Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Gilead Sciences in the fourth quarter valued at about $207,340,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the sale, the insider now directly owns 120,168 shares of the company’s stock, valued at approximately $13,238,908.56. The trade was a 2.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares of the company’s stock, valued at $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 48,500 shares of company stock valued at $5,236,245. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Wells Fargo & Company raised their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Morgan Stanley raised their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price objective for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $110.55.

Gilead Sciences Trading Down 1.2%

Shares of GILD opened at $105.93 on Thursday. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The firm has a 50 day simple moving average of $106.21 and a 200-day simple moving average of $103.03. Gilead Sciences, Inc. has a 1-year low of $66.01 and a 1-year high of $119.96. The stock has a market cap of $131.77 billion, a price-to-earnings ratio of 22.30, a price-to-earnings-growth ratio of 0.69 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences’s revenue for the quarter was down .3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.32) EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.98%. Gilead Sciences’s payout ratio is currently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.